MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes.
MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes.pdf
Biomarker; Diabetes; Diastolic dysfunction; Endothelial cell; Extracellular vesicle; Heart failure with preserved ejection fraction; Microvasculature; microRNA; Biomarkers; Fatty Acids; MIRN30 microRNA, rat; MicroRNAs; Mirn30d microRNA, mouse; Animals; Endothelial Cells/metabolism; Endothelial Cells/pathology; Fatty Acids/metabolism; Mice; Rats; Stroke Volume; Diabetes Mellitus, Type 2/diagnosis; Diabetes Mellitus, Type 2/genetics; Heart Failure; MicroRNAs/genetics; MicroRNAs/metabolism; Diabetes Mellitus, Type 2; Endothelial Cells; Internal Medicine; Endocrinology, Diabetes and Metabolism; Cardiology and Cardiovascular Medicine
Résumé :
[en] BACKGROUND: Type 2 diabetes (T2D) is associated with coronary microvascular dysfunction, which is thought to contribute to compromised diastolic function, ultimately culminating in heart failure with preserved ejection fraction (HFpEF). The molecular mechanisms remain incompletely understood, and no early diagnostics are available. We sought to gain insight into biomarkers and potential mechanisms of microvascular dysfunction in obese mouse (db/db) and lean rat (Goto-Kakizaki) pre-clinical models of T2D-associated diastolic dysfunction.
METHODS: The microRNA (miRNA) content of circulating extracellular vesicles (EVs) was assessed in T2D models to identify biomarkers of coronary microvascular dysfunction/rarefaction. The potential source of circulating EV-encapsulated miRNAs was determined, and the mechanisms of induction and the function of candidate miRNAs were assessed in endothelial cells (ECs).
RESULTS: We found an increase in miR-30d-5p and miR-30e-5p in circulating EVs that coincided with indices of coronary microvascular EC dysfunction (i.e., markers of oxidative stress, DNA damage/senescence) and rarefaction, and preceded echocardiographic evidence of diastolic dysfunction. These miRNAs may serve as biomarkers of coronary microvascular dysfunction as they are upregulated in ECs of the left ventricle of the heart, but not other organs, in db/db mice. Furthermore, the miR-30 family is secreted in EVs from senescent ECs in culture, and ECs with senescent-like characteristics are present in the db/db heart. Assessment of miR-30 target pathways revealed a network of genes involved in fatty acid biosynthesis and metabolism. Over-expression of miR-30e in cultured ECs increased fatty acid β-oxidation and the production of reactive oxygen species and lipid peroxidation, while inhibiting the miR-30 family decreased fatty acid β-oxidation. Additionally, miR-30e over-expression synergized with fatty acid exposure to down-regulate the expression of eNOS, a key regulator of microvascular and cardiomyocyte function. Finally, knock-down of the miR-30 family in db/db mice decreased markers of oxidative stress and DNA damage/senescence in the microvascular endothelium.
CONCLUSIONS: MiR-30d/e represent early biomarkers and potential therapeutic targets that are indicative of the development of diastolic dysfunction and may reflect altered EC fatty acid metabolism and microvascular dysfunction in the diabetic heart.
Disciplines :
Systèmes cardiovasculaire & respiratoire
Auteur, co-auteur :
Veitch, Shawn ✱; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Njock, Makon-Sébastien ✱; Université de Liège - ULiège > GIGA > GIGA I3 - Pneumology ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Chandy, Mark ✱; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada ; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA
Siraj, M Ahsan; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Chi, Lijun; Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Mak, HaoQi; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Yu, Kai; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Rathnakumar, Kumaragurubaran; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Perez-Romero, Carmina Anjelica; Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Chen, Zhiqi; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Alibhai, Faisal J; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Gustafson, Dakota; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Raju, Sneha; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Wu, Ruilin; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Zarrin Khat, Dorrin; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Wang, Yaxu; Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Caballero, Amalia; Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Meagher, Patrick; Keenan Biomedical Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
Lau, Edward; Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA
Pepic, Lejla; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA
Cheng, Henry S; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Galant, Natalie J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Howe, Kathryn L; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada ; Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
Li, Ren-Ke; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Connelly, Kim A; Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Husain, Mansoor; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Delgado-Olguin, Paul; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA ; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
Fish, Jason E ; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. jason.fish@utoronto.ca ; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada. jason.fish@utoronto.ca ; Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada. jason.fish@utoronto.ca
✱ Ces auteurs ont contribué de façon équivalente à la publication.
Langue du document :
Anglais
Titre :
MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes.
This work was supported by seed and team grant funding from the Canadian Vascular Network (to MH and JEF), a seed grant from the Ted Rogers Centre for Heart Research (TRCHR) (to PDO and JEF), and project grants from the Canadian Institutes of Health Research (CIHR) (to JEF; PJT148487 and PJT173489). JEF received infrastructure funding from the John R. Evans Leaders Fund and the Ontario Research Fund (Canada Foundation for Innovation) and is the recipient of a Tier II Canada Research Chair from CIHR. SV received funding from the Ontario Graduate Scholarship program and the TRCHR. M-SN received post-doctoral funding from the TRCHR and the Toronto General Hospital Research Institute. MC was supported by the Clinician Scientist Training Program and the Detweiler Traveling Fellowship from the Royal College of Physicians and Surgeons. DG received a Canada Graduate Scholarship from CIHR, an Ontario Graduate Scholarship and a studentship from TRCHR. FJA is supported by a CIHR post-doctoral fellowship. KR received post-doctoral fellowships from the Canadian Vascular Network and the TRCHR. PDO is supported by the Canadian Institutes of Health Research (CIHR) (PJT162208 and PJT149046), the Heart and Stroke Foundation of Canada (G-17-0018613), and the Natural Sciences and Engineering Research Council of Canada (NSERC) (500865). KAC is supported by a Merit Award from the Department of Medicine, the University of Toronto. The funding bodies did not play a role in the design of the study, analysis or interpretation of the data, nor did they play a role in the writing of the manuscript.
Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.
Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035–8.
Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277.e1-8.
Bouthoorn S, Valstar GB, Gohar A, den Ruijter HM, Reitsma HB, Hoes AW, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diabetes Vasc Dis Res. 2018;15(6):477–93.
Arnold SV, Echouffo-Tcheugui JB, Lam CSP, Inzucchi SE, Tang F, McGuire DK, et al. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). Am Heart J. 2018;203:25–9.
Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res. 2011;2(4):213–22.
Roh J, Houstis N, Rosenzweig A. Why don’t we have proven treatments for HFpEF? Circ Res. 2017;120(8):1243–5.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61
Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah AP, et al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018;314(5):H1033–42.
Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550–9.
Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018;39(10):840–9.
Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 2018;114(1):2.
De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154(3):651–63.
Sobczak IS, A, A Blindauer C, J Stewart A,. Changes in plasma free fatty acids associated with type-2 diabetes. Nutrients. 2019;11(9):2022.
Wan A, Rodrigues B. Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. Cardiovasc Res. 2016;111(3):172–83.
Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Investig. 2006;116(4):1071–80.
Engin AB. What Is lipotoxicity? Adv Exp Med Biol. 2017;960:197–220.
Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24(1):50.
Wang Y, Wang XJ, Zhao LM, Pang ZD, She G, Song Z, et al. Oxidative stress induced by palmitic acid modulates KCa2.3 channels in vascular endothelium. Exp Cell Res. 2019;383(2): 111552.
Gustafson D, Veitch S, Fish JE. Extracellular vesicles as protagonists of diabetic cardiovascular pathology. Front Cardiovasc Med. 2017;4:71.
Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28.
Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;1(3):24641.
Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et al. Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015;125(20):3202–12.
Horton WB, Barrett EJ. Microvascular dysfunction in diabetes mellitus and cardiometabolic disease. Endocr Rev. 2021;42(1):29–55.
Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng A, et al. Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis. 2018;9(2):82.
Katsuumi G, Shimizu I, Yoshida Y, Minamino T. Vascular senescence in cardiovascular and metabolic diseases. Front Cardiovasc Med. 2018;5:18.
Shakeri H, Lemmens K, Gevaert AB, De Meyer GRY, Segers VFM. Cellular senescence links aging and diabetes in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2018;315(3):H448–62.
Shosha E, Xu Z, Narayanan SP, Lemtalsi T, Fouda AY, Rojas M, et al. Mechanisms of diabetes-induced endothelial cell senescence: role of arginase 1. Int J Mol Sci. 2018;19(4):1215.
Laudato S, Patil N, Abba ML, Leupold JH, Benner A, Gaiser T, et al. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017;141(9):1879–90.
Sohn D, Peters D, Piekorz RP, Budach W, Janicke RU. miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3. Oncotarget. 2016;7(13):15915–29.
Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for cellular senescence. Proc Natl Acad Sci USA. 2017;114(23):E4612–20.
Flor AC, Kron SJ. Lipid-derived reactive aldehydes link oxidative stress to cell senescence. Cell Death Dis. 2016;7(9): e2366.
Yosef R, Pilpel N, Papismadov N, Gal H, Ovadya Y, Vadai E, et al. p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling. Embo J. 2017;36(15):2280–95.
Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–9.
Noren Hooten N, Evans MK. Techniques to induce and quantify cellular senescence. J Vis Exp. 2017;(123):55533.
Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43(W1):W460-6.
Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2020;48(D1):D148–54.
Kuo A, Lee MY, Sessa WC. Lipid droplet biogenesis and function in the endothelium. Circ Res. 2017;120(8):1289–97.
Lu Y, Qian L, Zhang Q, Chen B, Gui L, Huang D, et al. Palmitate induces apoptosis in mouse aortic endothelial cells and endothelial dysfunction in mice fed high-calorie and high-cholesterol diets. Life Sci. 2013;92(24–26):1165–73.
Hirota M, Kitagaki M, Itagaki H, Aiba S. Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress. J Toxicol Sci. 2006;31(2):149–56.
Ly LD, Xu S, Choi SK, Ha CM, Thoudam T, Cha SK, et al. Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes. Exp Mol Med. 2017;49(2): e291.
Fleissner F, Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal. 2011;15(4):933–48.
Forstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–35.
An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006;291(4):H1489–506.
Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2014;19(1):35–48.
Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997;34(1):25–33.
Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I, et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature. 2015;520(7546):192–7.
Kalucka J, Bierhansl L, Conchinha NV, Missiaen R, Elia I, Brüning U, et al. Quiescent endothelial cells upregulate fatty acid β-oxidation for vasculoprotection via redox homeostasis. Cell Metab. 2018;28(6):881-94.e13.
Huang H, McIntosh AL, Martin GG, Petrescu AD, Landrock KK, Landrock D, et al. Inhibitors of fatty acid synthesis induce PPAR alpha -regulated fatty acid beta -oxidative genes: synergistic roles of L-FABP and glucose. PPAR Res. 2013;2013: 865604.
Bonfigli AR, Spazzafumo L, Prattichizzo F, Bonafè M, Mensà E, Micolucci L, et al. Leukocyte telomere length and mortality risk in patients with type 2 diabetes. Oncotarget. 2016;7(32):50835–44.
Prattichizzo F, De Nigris V, Mancuso E, Spiga R, Giuliani A, Matacchione G, et al. Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biol. 2018;15:170–81.
Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 2011;108(2):522–7.
Gevaert AB, Shakeri H, Leloup AJ, Van Hove CE, De Meyer GRY, Vrints CJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. 2017;10(6):e003806
Palmer AK, Xu M, Zhu Y, Pirtskhalava T, Weivoda MM, Hachfeld CM, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging cell. 2019;18(3): e12950.
Pordzik J, Jakubik D, Jarosz-Popek J, Wicik Z, Eyileten C, De Rosa S, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18(1):113.
Zhang X, Dong S, Jia Q, Zhang A, Li Y, Zhu Y, et al. The microRNA in ventricular remodeling: the miR-30 family. Biosci Rep. 2019;39(8):BSR20190788
Yin Z, Zhao Y, He M, Li H, Fan J, Nie X, et al. MiR-30c/PGC-1beta protects against diabetic cardiomyopathy via PPARalpha. Cardiovasc Diabetol. 2019;18(1):7.
Li J, Salvador AM, Li G, Valkov N, Ziegler O, Yeri A, et al. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling. Circ Res. 2021;128(1):e1–23.
Li X, Du N, Zhang Q, Li J, Chen X, Liu X, et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Cell Death Dis. 2014;5(10): e1479.
Zhang WY, Wang J, Li AZ. A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d/KLF9/VEGFA pathway. Eur Rev Med Pharmacol Sci. 2020;24(11):6346–59.
Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74–85.
